Jun 21, 2022
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing

Jun 13, 2022
AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention

May 19, 2022
AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022
AIM ImmunoTech Provides Update on Ampligen Long COVID Development Program

May 16, 2022
AIM ImmunoTech Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022
AIM ImmunoTech to Participate in a Solve M.E. Signature Event: 'Long COVID: Research, Policy, and Economic Impact' on May 19, 2022

Apr 21, 2022
AIM ImmunoTech Provides Summary of Ampligen® Data Supporting Synergistic Potential with Checkpoint Blockade Therapies

Apr 12, 2022
AIM ImmunoTech Provides Progress on Advancement of Ampligen® Clinical Development Program for the Treatment of Pancreatic Cancer

Apr 11, 2022
AIM ImmunoTech Announces Positive Data from Phase 2a Study Evaluating Ampligen® as a Component of a Chemokine Modulatory (CKM) Regimen for the Treatment of Colorectal Cancer Metastatic to the Liver

Apr 11, 2022
AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

   1    2   3   4   5   6